Saxenda weight loss claims on TikTok: what 21 lbs in 5 weeks actually means

What did @hairbylyndsayb actually say?

She reported losing 21 pounds in five weeks on Saxenda (liraglutide), said she just reached the maximum dose of 3.0 mg, and described constipation as her worst side effect. She also called Saxenda "a lot like Wegovy," which is a comparison worth examining carefully.

To her credit, she did not claim Saxenda cures anything, did not recommend a specific dose to viewers, and was upfront about her side effects. The core claims here are: (1) 21 pounds in five weeks is real, (2) 3.0 mg is the "full dosage," and (3) Saxenda and Wegovy are similar medications. Those are all checkable, and the answers are more complicated than her video suggests.

Does the science back this up?

Partly. The clinical data on liraglutide supports meaningful weight loss, but 21 pounds in five weeks is far above average, and the drug comparison she made is imprecise enough to mislead viewers who are shopping for their own treatment.

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) found that patients on 3.0 mg liraglutide lost an average of 8.4 kg (about 18.5 lbs) over 56 weeks, not five. Losing 21 pounds in five weeks would require a caloric deficit far beyond what liraglutide alone typically produces. That does not mean she is lying. It means she may have significant water weight loss in the early weeks, possibly a stricter diet than she mentioned, or natural variation. But her results are statistical outliers, not the norm.

On the Saxenda-Wegovy comparison: liraglutide (Saxenda) and semaglutide (Wegovy) are both GLP-1 receptor agonists, but they are different molecules with different half-lives, dosing schedules, and efficacy profiles. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide produced roughly twice the weight loss of liraglutide in head-to-head comparisons. Calling them similar is a stretch.

What did they get wrong (or right)?

She got the side effect picture basically right. The dose framing needs a correction. And the Wegovy comparison is where she drifts into territory that could genuinely confuse people.

Constipation is real and well-documented with GLP-1 agonists. A 2022 systematic review (Zhao et al., Diabetes, Obesity and Metabolism) confirmed constipation affects 11-19% of liraglutide users, often requiring intervention. Her experience tracks with the data.

On dosing: she said "I'll be on this dosage forever." The 3.0 mg dose is the approved maintenance dose for weight management in Saxenda's label, not a stopping point or ceiling tied to a goal weight. Framing it as a finish line could mislead viewers into thinking they will eventually taper off, which is not how GLP-1 therapy typically works. Most patients who stop regain weight.

The Wegovy comparison is the biggest issue. Yes, both are GLP-1 agonists. But they are not interchangeable, not equivalent, and do not produce the same outcomes. Viewers who hear "it's a lot like Wegovy" may assume the results are the same or that one can substitute for the other. That is not supported by the evidence.

What should you actually know?

Saxenda is a legitimate, FDA-approved medication for chronic weight management. But early dramatic results are not the standard, and the comparison to Wegovy understates real differences between these drugs.

If you are considering Saxenda or any GLP-1 therapy, a few things matter more than a TikTok result. First, average weight loss on liraglutide 3.0 mg is roughly 5-8% of body weight over a year, not 21 pounds in a month. Second, weight regain after stopping is common, with studies showing patients regain two-thirds of lost weight within a year of discontinuation (Rubino et al., 2021, JAMA). Third, GLP-1 medications are not a short-term fix. The framing of "until I reach my goal" suggests she may plan to stop, which is a conversation she should be having with her prescriber, not announcing to TikTok.

• Saxenda requires a titration schedule to reach 3.0 mg, typically over 4-5 weeks, exactly as described.
• Constipation management during GLP-1 therapy is a legitimate clinical concern, not a minor inconvenience.
• Individual results vary significantly. Outlier cases like this one do not represent what most patients will experience.